Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an announcement.
Botanix Pharmaceuticals Limited has issued 3,990,099 new fully paid ordinary shares, which can now be traded immediately under the exemption provided by section 708A(5) of the Corporations Act 2001. This move aligns with the company’s compliance with relevant provisions of the Corporations Act, potentially enhancing its market liquidity and investor engagement.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, specializing in innovative treatments for skin conditions. The company has received FDA approval for its lead product, Sofdra™, which is the first and only new chemical entity approved to treat primary axillary hyperhidrosis, offering a novel solution for patients with limited treatment options.
YTD Price Performance: 7.95%
Average Trading Volume: 5,954,681
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$867.2M
See more insights into BOT stock on TipRanks’ Stock Analysis page.